Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika to Present at the Singular Research Summer Solstice Conference on July 13, 2017
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief Executive Officer, Charles H.
View HTML
Toggle Summary Anika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress
BEDFORD, Mass. & VIENNA --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to present Phase III data on CINGAL ® , its novel
View HTML
Toggle Summary Anika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the enrollment of the first patient in its supplemental Phase III
View HTML
Toggle Summary Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded and Consolidated Global Manufacturing Facility in Bedford, Massachusetts
Ribbon-Cutting Ceremony Opens the Doors to State-of-the-Art Facility Built to Supply Global Demand for Anika's Extensive Commercial Portfolio of More than 20 Products and Technologies BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics
View HTML
Toggle Summary Anika Announces Publication of Phase III Data Demonstrating the Efficacy and Safety of CINGAL® for the Treatment of Knee Pain Associated with Osteoarthritis
Positive Data Provides Further Rationale for Strong and Growing Physician Demand for CINGAL following Commercial Launches in Europe and Canada BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics
View HTML
Toggle Summary Anika Reports First Quarter 2017 Financial Results
MONOVISC Revenue Increases 24% Year-over-Year Total Revenue Grows 5% Year-over-Year Commercially Launches ORTHOVISC-T in Europe BEDFORD, Mass. , May 03, 2017 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedic medicines company specializing in therapeutics
View HTML
Toggle Summary Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call the next day, Thursday, May 4, 2017 , at 9:00
View HTML
Toggle Summary Anika to Present at the 2017 Canaccord Genuity Musculoskeletal Conference on March 14, 2017
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief Executive Officer, Charles H.
View HTML
Toggle Summary Anika Reports Fourth Quarter and Full Year 2016 Financial Results
Worldwide Orthobiologics Revenue Increases 13% Year-over-Year for Fourth Quarter of 2016 Product Revenue Grows 17% for Full Year of 2016 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based
View HTML
Toggle Summary Anika to Issue Fourth-Quarter 2016 Financial Results and Business Highlights on Wednesday, February 15
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2016 financial results after the close of the market on Wednesday, February 15, 2017 and to hold a conference call the next day, Thursday, February 16, 2017
View HTML